Novo Nordisk faces limited upside from ZEUS trial as patent cliff looms, Deutsche Bank warns
Deutsche Bank expects Novo Nordisk's (NYSE:NVO) pending ZEUS trial to miss, but sees limited upside even if the drug proves successful, given the company's looming patent cliff. The analyst has set a target of DKK290, just 3.6% above the last closing price of DKK280.10, and maintains a hold rating on the stock.